文献速递病毒性肝炎

HBV来源合成长肽可在体外增强慢性HBV患者的CD4+和CD8+ T细胞应答

HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo.
PubMed 文献 · J Infect Dis · 2018-01-01

本研究探讨HBV核心序列来源的合成长肽(SLP)在体外增强慢性乙型肝炎(CHB)患者HBV特异性T细胞的能力。负载SLP的患者来源单核细胞衍生树突状细胞(moDC)显著增加自体HBcAg18-27特异性CD8+和CD4+ T细胞,且这些T细胞可合成肿瘤坏死因子-α和干扰素-γ;6/7例患者中阻断PD-L1进一步增强SLP效应。患者来源BDCA1+髓系DC亦可在体外交叉呈递并激活自体T细胞应答。

要点

  • HBc-SLP可被moDC交叉呈递,佐剂可进一步增强该交叉呈递。
  • 负载SLP的患者moDC在体外显著增加自体HBcAg18-27特异性CD8+和CD4+ T细胞。
  • 6/7例患者中阻断PD-L1进一步增强SLP效应。

核心结论

  • 概念验证显示原型HBc-SLP可在体外增强CHB患者的T细胞应答。
  • 结果为开发基于SLP的治疗性疫苗以诱导CHB患者有效的HBV特异性适应性免疫应答铺平道路。

研究设计与样本

  • 体外研究:用HBc-SLP评估moDC和BDCA1+血液髓系DC对工程化HBV特异性CD8+ T细胞的交叉呈递。
  • 用负载SLP并经Toll样受体(TLR)刺激的自体DC激活患者HBc特异性CD8+和CD4+ T细胞。

主要发现

  • HBV-SLP可被moDC交叉呈递,佐剂可进一步增强该交叉呈递。
  • 负载SLP的患者来源moDC在体外显著增加自体HBcAg18-27特异性CD8+ T细胞和CD4+ T细胞。
  • HBV特异性T细胞具有功能,可合成肿瘤坏死因子-α和干扰素-γ。
  • 6/7例患者中阻断PD-L1进一步增强SLP效应。
  • 患者来源BDCA1+髓系DC在体外交叉呈递并激活自体T细胞应答。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination with synthetic long peptides (SLP) is a promising new treatment strategy for chronic hepatitis B virus (CHB). SLP can induce broad T-cell responses for all HLA types. Here we investigated the ability of a prototype HBV-core (HBc)-sequence-derived SLP to boost HBV-specific T cells in CHB patients ex vivo. METHODS: HBc-SLP was used to assess cross-presentation by monocyte-derived dendritic cells (moDC) and BDCA1+ blood myeloid DC (mDC) to engineered HBV-specific CD8+ T cells. Autologous SLP-loaded and toll-like receptor (TLR)-stimulated DC were used to activate patient HBc-specific CD8+ and CD4+ T cells. RESULTS: HBV-SLP was cross-presented by moDC, which was further enhanced by adjuvants. Patient-derived SLP-loaded moDC significantly increased autologous HBcAg18-27-specific CD8+ T cells and CD4+ T cells ex vivo. HBV-specific T cells were functional as they synthesized tumor necrosis factor-alpha and interferon-gamma. In 6/7 of patients blockade of PD-L1 further increased SLP effects. Also, importantly, patient-derived BDCA1+ mDC cross-presented and activated autologous T-cell responses ex vivo. CONCLUSIONS: As a proof of concept, we showed a prototype HBc-SLP can boost T-cell responses in patients ex vivo. These results pave the way for the development of a therapeutic SLP-based vaccine to induce effective HBV-specific adaptive immune responses in CHB patients.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dou Y, van Montfoort N, van den Bosch A, et al. HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo. J Infect Dis. 2018. PMID: 29220492. doi:10.1093/infdis/jix614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。